Drug Approval | June 27, 2025
Lupin launches Prucalopride tablets in US
Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA
Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA
J B Chemicals and Pharmaceuticals receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA
Prucalopride Tablets are indicated for the treatment of chronic idiopathic constipation in adults
UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials
Sun Pharma gets 8 observations from USFDA for Halol facility
Zydus receives EIR for the API manufacturing facility at Ankleshwar
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
Oxcarbazepine ER Tablets (RLD Oxtellar XR) had estimated annual sales of US$ 206 million in the US (IQVIA MAT April 2025)
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Subscribe To Our Newsletter & Stay Updated
